Vaccine manufacturing is one of the most demanding areas of pharmaceutical production. A vaccine manufacturing plant must support complex biological processes while maintaining stringent standards for contamination control, environmental conditions, quality assurance and process consistency.
At the same time, vaccine demand can change quickly. Manufacturers may need to increase capacity, introduce new vaccine technologies, respond to public health requirements or establish production closer to the markets they serve.
This creates an important question:
How can manufacturers build vaccine manufacturing capacity quickly without compromising flexibility, quality or long-term performance?
A modular vaccine manufacturing facility can be part of the answer.
Modular construction allows significant portions of a facility to be fabricated, assembled and tested away from the final site before being installed. WHO’s vaccine GMP training materials specifically identify modularisation as an approach that can move much of the construction work into a dedicated fabrication environment, potentially reducing the time required for construction, qualification and validation.
But setting up a modular vaccine facility isn’t simply a matter of putting production equipment inside prefabricated rooms. The modular approach has to begin with the manufacturing process itself.
Start with the vaccine manufacturing process.
Every vaccine manufacturing facility is shaped by the product it is intended to make.
The process may involve stages such as antigen production, harvesting, purification, formulation, filling and packaging, depending on the vaccine platform. Different technologies also have different requirements for biosafety, containment, environmental control, utilities and equipment.
This means the first step in vaccine manufacturing facility design should be defining the process requirements.
Questions to answer include:
- What vaccine(s) will be manufactured?
- What is the expected batch size?
- What production capacity is required?
- Will the facility manufacture one product or multiple products?
- Which process steps will take place on site?
- What level of containment is required?
- Will production use single-use or stainless-steel systems?
- What are the requirements for formulation and filling?
- What quality control and analytical laboratories are required?
- How much future expansion should the facility accommodate?
These decisions influence everything from room layouts and material flows to HVAC systems, utilities and equipment selection.
WHO’s vaccine prequalification guidance, for example, expects manufacturers to document manufacturing and quality-control areas, air and material flows, room classifications, ventilation systems, water systems, equipment, cleaning procedures, and qualification and validation procedures.
In other words, facility design has to follow the manufacturing process, not the other way around.
What does vaccine manufacturing facility design need to consider?
A vaccine manufacturing facility needs carefully planned segregation and controlled movement of people, materials, products and waste.
This is particularly important where there are contamination or cross-contamination risks. The facility layout should support logical movement through the manufacturing process while preventing unnecessary interaction between different flows.
Depending on the vaccine and process, the design may need to accommodate:
Controlled manufacturing areas.
Manufacturing rooms need finishes, environmental conditions and layouts appropriate for their intended use. Cleanroom classifications and environmental controls will depend on the specific manufacturing operations being performed.
HVAC and air handling.
Air handling is a major component of vaccine manufacturing facility design. Pressure relationships, air changes, filtration, temperature, humidity and room classifications need to be considered alongside the process and contamination-control strategy.
Water systems.
Pharmaceutical water systems need to be designed around the requirements of the manufacturing process. WHO guidance notes that vaccine manufacturing documentation should describe water systems, including storage, distribution loops, points of use, sampling points and sanitation procedures.
Utilities.
A facility may require systems for purified water or WFI (water for injection), clean steam, compressed gases, electrical power, HVAC and other process-specific utilities.
Quality control.
Laboratories and sampling areas need to be integrated into the facility rather than treated as an afterthought. Testing requirements can influence both the layout and the movement of samples through the facility.
Personnel and material flows.
Personnel entry, gowning, material transfer and waste movement should all be considered during the design stage.
At the end of the day, the goal is not simply to create rooms that meet a specification. It is to create a facility in which the entire manufacturing workflow supports GMP requirements.
Where does modular construction fit?
This is where modular construction becomes interesting.
Not every part of a vaccine manufacturing plant needs to be constructed in exactly the same way.
A traditional stick-built approach may make sense for permanent structural elements and infrastructure. Modular construction, meanwhile, can be particularly useful for areas where speed, repeatability and future flexibility are important.
For example, modular solutions may be considered for:
- Cleanroom environments
- Process rooms
- Laboratories
- Gowning areas
- Technical spaces
- Utility modules
- Support areas
- Expansion modules
The precise application depends on the project.
This is important because a modular vaccine manufacturing facility does not have to mean a 100% modular facility.
In fact, a hybrid approach can sometimes make more sense. Different parts of a high-tech facility can have different requirements, and combining conventional construction with modular and prefabricated solutions can provide a better balance of durability, flexibility and speed.
Why modularisation can make sense for vaccine manufacturing.
One of the biggest advantages of modularisation is that some work can happen away from the construction site.
Instead of fabricating every component on site, modules can be manufactured in a controlled environment and transported to the project location. This can potentially reduce the amount of site-based work and dependence on local skilled labour. It can also allow multiple activities to happen in parallel rather than forcing every stage of construction to follow a single sequential timeline.
For vaccine manufacturing projects, where cleanroom construction/installation and controlled environments are particularly important, shifting more work into a controlled fabrication environment can have practical advantages.
There is another benefit: repeatability.
If a manufacturer expects to expand capacity over time, designing standardised modules from the beginning can make subsequent expansion more straightforward. That could be particularly valuable for manufacturers dealing with uncertain demand or developing multiple products.
Designing for expansion.
Vaccine manufacturing capacity shouldn’t necessarily be designed only around today’s requirements.
Demand can change. Production may move from clinical to commercial scale. New vaccine technologies may be introduced. A manufacturer may need additional filling capacity, new formulation areas or additional quality-control capabilities.
A modular approach can allow some of these future requirements to be considered from the beginning.
Instead of asking, “How large does this facility need to be today?”, the better question may be, “How does this facility need to evolve over the next five, ten or fifteen years?”
That changes the approach to facility design. Expansion zones, utility capacity, structural interfaces and connection points can all be considered early, reducing the need for disruptive modifications later.
Modular does not mean compromising on GMP.
A common misconception is that modular construction is primarily about speed.
Speed matters, but it cannot come at the expense of GMP.
WHO states that GMP applies to the premises, systems, utilities, equipment, personnel and processes involved in pharmaceutical and biological production, including vaccines. These elements need to be appropriately designed, controlled, validated and documented.
That means modular components still need to be designed around the same fundamental quality requirements as conventionally constructed facilities.
Qualification and validation also need to be considered from the beginning. WHO’s validation guidance covers activities including design qualification, factory acceptance testing, installation qualification, operational qualification and performance qualification.
This is why modular vaccine facility design should involve engineering, manufacturing, quality and validation teams early in the project.
The objective isn’t simply to build faster. It is to create a facility that can be qualified, validated, operated and expanded reliably.
A final word.
Setting up a modular vaccine manufacturing facility begins long before the first module is fabricated.
The project needs to start with the vaccine manufacturing process, define the quality and regulatory requirements, map personnel and material flows, establish utility and environmental requirements, and determine which parts of the facility benefit from modularisation.
The result may be fully modular, conventionally built, or a combination of both. The important thing is to choose the construction model according to the requirements of the facility.
In part 2, we’ll look at the economics of modular vaccine facilities, including what drives modular vaccine manufacturing facility cost, how to approach qualification and validation, and why a hybrid construction model may be the right choice for some vaccine manufacturing projects.
Setting up a modular vaccine manufacturing facility: What it takes | Part 2
Modular vaccine manufacturing facility cost, compliance and execution.
Building a vaccine manufacturing facility is a significant capital project. But the headline construction cost is only one part of the equation.
A vaccine manufacturing plant also needs sophisticated utilities, environmental controls, process equipment, quality-control infrastructure, qualification and validation. It needs to be designed around regulatory expectations and, ideally, around the manufacturer’s future production requirements.
For this reason, asking “What does a modular vaccine manufacturing facility cost?” without defining the project can produce a misleading answer.
The more useful question is, “What factors determine the total cost of establishing a modular vaccine manufacturing facility?”
What determines modular vaccine manufacturing facility cost?
There is no single cost figure that applies to every modular vaccine facility.
The cost can vary substantially depending on the vaccine platform, production capacity, level of containment, cleanroom requirements, process equipment, site conditions and degree of modularisation.
Some of the biggest cost drivers include:
1. Production capacity.
A facility designed for small-scale clinical or pilot production will have very different requirements from a commercial-scale vaccine manufacturing plant. Capacity affects the size of manufacturing spaces, equipment, storage, utilities, laboratories and supporting infrastructure.
2. Vaccine technology.
The manufacturing process has a major influence on the facility. Different vaccine platforms can require different process equipment, environmental controls, containment measures and utility requirements. The facility therefore needs to be designed around the specific product and process rather than around a generic “vaccine facility” template.
3. Cleanroom requirements.
The number and classification of controlled areas can have a significant impact on both construction and operating costs. HVAC, filtration, pressure control, monitoring systems and specialised finishes all contribute to the cost of a controlled manufacturing environment.
4. Process equipment.
Process equipment can represent a substantial part of overall project expenditure. Depending on the process, this may include bioreactors, purification systems, formulation equipment, filling systems, autoclaves, freezers, cold-storage systems and other specialised equipment.
5. Utilities.
Utilities are another major consideration. Water systems, HVAC, clean steam, compressed gases, electrical systems and other process utilities need to be appropriately designed and sized. WHO’s qualification guidance specifically identifies systems such as water purification, HVAC, compressed air, gas and steam systems among the systems that may need qualification.
6. Site conditions.
A modular solution can reduce certain site-based construction activities, but the site still matters. Available infrastructure, power supply, water availability, transportation access, existing buildings and local construction capabilities can all influence the project. The more challenging the site, the more important early engineering and planning become.
Does modular construction make a vaccine facility cheaper?
Not necessarily. And this is an important distinction.
Modular construction should not automatically be sold as a way to make every project cheaper. Instead, its value can come from how it changes the project timeline, execution model, labour requirements, quality control and future flexibility.
Some costs may increase because modules require detailed engineering, factory fabrication, transportation and specialised integration. At the same time, some site activities can be reduced or moved off-site.
A modular approach can also enable parallel workstreams. While site preparation and foundations are underway, modules can be fabricated elsewhere. That can potentially shorten the overall project schedule. And time has an economic value.
Earlier commissioning can mean earlier production. Faster expansion can mean earlier access to additional capacity. Reduced disruption during future modifications can also have operational value.
So when evaluating modular vaccine manufacturing facility cost, it is better to look beyond the initial construction quotation. Instead, consider the total project and lifecycle cost.
The case for a hybrid vaccine manufacturing facility.
There is an option between conventional construction and a fully modular facility: a hybrid model.
The basic principle is straightforward:
Use conventional construction where permanence, structural integration and site-specific requirements make sense. Use prefabricated and modular systems where speed, flexibility and repeatability provide an advantage.
Rather than treating conventional and modular construction as competing approaches, the facility can be broken into different areas and each area can use the approach best suited to its requirements.
For a vaccine manufacturing project, this could mean a permanent core building containing structural infrastructure and major utilities, combined with modular cleanroom or process areas. The exact configuration depends on the manufacturing process and project requirements.
Qualification and validation need to start early.
One of the biggest mistakes in facility development is treating qualification and validation as something that happens after construction.
For a vaccine manufacturing facility, they need to influence the project from the beginning. WHO guidance describes qualification as documented evidence that premises, systems, utilities and equipment have been designed, installed and operated appropriately for their intended purpose.
That means the project needs a clear understanding of:
- User requirements
- Design requirements
- Equipment specifications
- Utility requirements
- Factory acceptance testing
- Installation qualification
- Operational qualification
- Performance qualification
- Cleaning and process validation
- Environmental monitoring
When modular components are fabricated away from the final site, factory testing can become particularly relevant. Some systems can be inspected and tested before they reach the site, reducing the amount of work that needs to be completed after installation.
But this does not eliminate site qualification. The completed facility still needs to demonstrate that its systems work together as intended in the actual operating environment.
Building flexibility into the facility.
The value of a modular vaccine manufacturing facility becomes even more apparent when future requirements are uncertain.
Imagine a manufacturer establishing a facility for one vaccine today but expecting additional products in the future.
A rigid facility may require significant construction work to accommodate those products. A modular or hybrid facility can instead be designed around future interfaces. That could include provisions for additional process areas, expansion modules, utility connections or additional manufacturing capacity. This is particularly relevant as vaccine manufacturing becomes more diverse and manufacturers increasingly need to support multiple products and technologies.
Flexibility needs to be considered alongside compliance, rather than instead of it.
Choosing the right construction model.
So, should a vaccine manufacturer choose a modular facility? There isn’t a universal answer. The right approach depends on the project.
A fully modular solution may make sense when speed, repeatability and deployment flexibility are major priorities.
A conventional facility may be appropriate where the project has highly specific structural or site requirements.
A hybrid facility may be more appropriate where the project needs to combine permanent infrastructure with flexible, prefabricated manufacturing environments.
This is why the decision should be made after assessing the manufacturing process, site, capacity, timeline, regulatory requirements and future expansion plans.
The goal isn’t to use modular construction because it is fashionable. It is to use it where it solves a genuine project problem.
A practical approach to setting up a modular vaccine manufacturing facility.
A project can broadly be approached through the following stages:
1. Define the manufacturing process. Establish the vaccine platform, production scale, batch sizes and process requirements.
2. Establish regulatory and GMP requirements. Identify the applicable regulatory framework, facility standards, biosafety requirements and quality expectations.
3. Develop the facility concept. Map manufacturing, QC, storage, personnel and material flows.
4. Define utilities and equipment. Establish the requirements for HVAC, water, steam, gases, power and process equipment.
5. Identify what should be modular. Determine which facility areas would benefit from prefabrication and which are better addressed through conventional construction.
6. Design for qualification and validation. Build testing, documentation and validation requirements into the design rather than adding them later.
7. Plan future expansion. Identify potential production changes and establish interfaces that can accommodate future growth.
8. Fabricate, construct and integrate. Where appropriate, modules can be fabricated and tested off-site while site works progress in parallel.
9. Qualify and validate. Verify that premises, utilities, equipment and processes perform as intended.
10. Commission and operate. The final objective is not simply a completed building. It is a qualified manufacturing facility capable of producing vaccines consistently and reliably.
Choosing the right construction model.
A modular vaccine manufacturing facility can offer a different way of approaching one of the most complex types of pharmaceutical infrastructure.
But modularisation isn’t a shortcut around good engineering or GMP.
The facility still needs appropriate cleanrooms, utilities, equipment, environmental controls, quality systems and validation. What modular construction changes is how some of that infrastructure is delivered.
For manufacturers looking at vaccine capacity in new markets, expanding existing production or preparing for future demand, the most useful question may therefore not be whether to choose modular or conventional construction.
It may be, which parts of our vaccine manufacturing facility should be modular, which should be conventionally built, and how can the two work together?
That is where a hybrid or fusion approach can become valuable. By combining permanent infrastructure with prefabricated and modular environments where they make the most sense, manufacturers can design facilities around their actual operational needs rather than forcing the entire project into a single construction model.
And when the requirements of vaccine manufacturing change, the facility can be designed to change with them. That’s the most important advantage of going the hybrid way.
